Safety and Immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
Phase of Trial: Phase II
Latest Information Update: 27 May 2016
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Sanofi
- 07 Nov 2015 Results published in the Vaccine
- 12 Aug 2011 Actual end date 1 April 2011 added as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.